Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexicon Pharmaceuticals, Inc. - Common Stock (NQ:LXRX)

1.370 -0.020 (-1.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,459,637
Open 1.390
Bid (Size) 1.380 (5)
Ask (Size) 1.450 (6)
Prev. Close 1.390
Today's Range 1.360 - 1.410
52wk Range 0.2836 - 2.075
Shares Outstanding 144,474,452
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain
Diverse group of stakeholders aligned around the importance of elevating public awareness of need for new treatments for chronic pain and the need to expand the Alternatives to PAIN Act 
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
+76.3%
+76.3%
1 Month
-1.4%
-1.4%
3 Month
+28.0%
+28.0%
6 Month
+104.8%
+104.8%
1 Year
-26.3%
-26.3%

More News

Read More
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Topics Stocks
Earnings Scheduled For August 6, 2025
Via Benzinga
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon (LXRX) Q2 Revenue Soars 1,706%
Via The Motley Fool
Topics Intellectual Property
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Q2 2025 Earnings: Revenue Soars 482% Above Estimates, Stock Gains 9.5%
Via Chartmill
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
A Preview Of Lexicon Pharmaceuticals's Earnings
Via Benzinga
Earnings Scheduled For May 13, 2025
Via Benzinga
Top 2 Health Care Stocks That May Crash This Month
Via Benzinga
Curious about the most active stocks on Monday?
Via Chartmill
US Stocks Likely To Open Lower After 3-Day Fall: 'Equity Drawdown Probability Hasn't Peaked Yet,' Says Goldman Sachs Analyst
Via Benzinga
While Wall Street Panicked, These 3 Hidden Small-Caps Exploded Last Week — One Surging A Jaw-Dropping 60%
Via Benzinga
Topics Economy

Frequently Asked Questions

Is Lexicon Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Lexicon Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Lexicon Pharmaceuticals, Inc. - Common Stock trade on?
Lexicon Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lexicon Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Lexicon Pharmaceuticals, Inc. - Common Stock is LXRX on the Nasdaq Stock Market
What is the current price of Lexicon Pharmaceuticals, Inc. - Common Stock?
The current price of Lexicon Pharmaceuticals, Inc. - Common Stock is 1.370
When was Lexicon Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Lexicon Pharmaceuticals, Inc. - Common Stock was at 10/28/25 04:00 PM ET
What is the market capitalization of Lexicon Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Lexicon Pharmaceuticals, Inc. - Common Stock is 197.93M
How many shares of Lexicon Pharmaceuticals, Inc. - Common Stock are outstanding?
Lexicon Pharmaceuticals, Inc. - Common Stock has 198M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.